targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000065518 | MONDO_0005148 | NCT00121667 | Completed | 3 | 2005-08-01 | null | null | null | Phase III+ | Phase II+ | 377,957,122,341 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121667 | Completed | 3 | 2005-08-01 | null | null | null | Phase III+ | Phase II+ | 377,957,122,341 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121667 | Completed | 3 | 2005-08-01 | null | null | null | Phase III+ | Phase II+ | 377,957,122,341 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03377335 | Unknown status | 4 | 2017-12-22 | null | null | Phase IV | Phase III+ | Phase II+ | 395,136,991,590 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03377335 | Unknown status | 4 | 2017-12-22 | null | null | Phase IV | Phase III+ | Phase II+ | 395,136,991,590 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03377335 | Unknown status | 4 | 2017-12-22 | null | null | Phase IV | Phase III+ | Phase II+ | 395,136,991,590 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01869621 | Completed | 1 | 2013-04-01 | null | null | null | null | null | 395,136,991,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01869621 | Completed | 1 | 2013-04-01 | null | null | null | null | null | 395,136,991,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01869621 | Completed | 1 | 2013-04-01 | null | null | null | null | null | 395,136,991,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01779375 | Completed | 3 | 2013-06-16 | null | null | null | Phase III+ | Phase II+ | 395,136,992,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01779375 | Completed | 3 | 2013-06-16 | null | null | null | Phase III+ | Phase II+ | 395,136,992,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01779375 | Completed | 3 | 2013-06-16 | null | null | null | Phase III+ | Phase II+ | 395,136,992,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01510522 | Withdrawn | 4 | 2012-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 403,726,925,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01510522 | Withdrawn | 4 | 2012-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 403,726,925,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01510522 | Withdrawn | 4 | 2012-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 403,726,925,850 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03214380 | Completed | 3 | 2017-07-14 | null | null | null | Phase III+ | Phase II+ | 403,726,926,798 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03214380 | Completed | 3 | 2017-07-14 | null | null | null | Phase III+ | Phase II+ | 403,726,926,798 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03214380 | Completed | 3 | 2017-07-14 | null | null | null | Phase III+ | Phase II+ | 403,726,926,798 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01841697 | Completed | 3 | 2013-06-13 | null | null | null | Phase III+ | Phase II+ | 403,726,927,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01841697 | Completed | 3 | 2013-06-13 | null | null | null | Phase III+ | Phase II+ | 403,726,927,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01841697 | Completed | 3 | 2013-06-13 | null | null | null | Phase III+ | Phase II+ | 403,726,927,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03018665 | Not yet recruiting | 4 | 2017-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 403,726,927,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03018665 | Not yet recruiting | 4 | 2017-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 403,726,927,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03018665 | Not yet recruiting | 4 | 2017-02-01 | null | null | Phase IV | Phase III+ | Phase II+ | 403,726,927,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01305551 | Withdrawn | 1 | 2011-03-01 | Withdrawn | stopped | null | null | null | 403,726,927,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01305551 | Withdrawn | 1 | 2011-03-01 | Withdrawn | stopped | null | null | null | 403,726,927,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01305551 | Withdrawn | 1 | 2011-03-01 | Withdrawn | stopped | null | null | null | 403,726,927,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01929863 | Completed | 2 | 2013-08-01 | null | null | null | null | Phase II+ | 438,086,664,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01929863 | Completed | 2 | 2013-08-01 | null | null | null | null | Phase II+ | 438,086,664,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01929863 | Completed | 2 | 2013-08-01 | null | null | null | null | Phase II+ | 438,086,664,488 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00918138 | Completed | 3 | 2009-08-01 | null | null | null | Phase III+ | Phase II+ | 438,086,664,806 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00918138 | Completed | 3 | 2009-08-01 | null | null | null | Phase III+ | Phase II+ | 438,086,664,806 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00918138 | Completed | 3 | 2009-08-01 | null | null | null | Phase III+ | Phase II+ | 438,086,664,806 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02002221 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 438,086,665,000 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02002221 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 438,086,665,000 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02002221 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 438,086,665,000 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00376038 | Completed | 1 | 2006-08-01 | null | null | null | null | null | 438,086,666,155 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00376038 | Completed | 1 | 2006-08-01 | null | null | null | null | null | 438,086,666,155 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00376038 | Completed | 1 | 2006-08-01 | null | null | null | null | null | 438,086,666,155 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00366301 | Terminated | 4 | 2006-08-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 446,676,599,087 | Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08. | Phase 4 | 31/08/2006 | Terminated | 25/11/2010 | 30/04/2009 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00366301 | Terminated | 4 | 2006-08-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 446,676,599,087 | Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08. | Phase 4 | 31/08/2006 | Terminated | 25/11/2010 | 30/04/2009 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00366301 | Terminated | 4 | 2006-08-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 446,676,599,087 | Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08. | Phase 4 | 31/08/2006 | Terminated | 25/11/2010 | 30/04/2009 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00474838 | Completed | 4 | 2007-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 446,676,600,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00474838 | Completed | 4 | 2007-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 446,676,600,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00474838 | Completed | 4 | 2007-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 446,676,600,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02526615 | Completed | 4 | 2000-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,337,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02526615 | Completed | 4 | 2000-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,337,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02526615 | Completed | 4 | 2000-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,337,340 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01117350 | Completed | 4 | 2010-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,338,317 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01117350 | Completed | 4 | 2010-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,338,317 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01117350 | Completed | 4 | 2010-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 481,036,338,317 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941148 | Completed | 4 | 2008-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,106 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941148 | Completed | 4 | 2008-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,106 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00941148 | Completed | 4 | 2008-04-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,106 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01947790 | Completed | 4 | 2013-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,286 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01947790 | Completed | 4 | 2013-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,286 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01947790 | Completed | 4 | 2013-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 489,626,272,286 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01217892 | Completed | 3 | 2010-11-01 | null | null | null | Phase III+ | Phase II+ | 489,626,272,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01217892 | Completed | 3 | 2010-11-01 | null | null | null | Phase III+ | Phase II+ | 489,626,272,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01217892 | Completed | 3 | 2010-11-01 | null | null | null | Phase III+ | Phase II+ | 489,626,272,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698789 | Terminated | 2 | 2008-05-01 | Terminated | stopped | null | null | Phase II+ | 489,626,273,281 | Study ended after diabetes development plan review. . | Phase 2 | 31/05/2008 | Terminated | 30/10/2012 | 30/06/2009 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698789 | Terminated | 2 | 2008-05-01 | Terminated | stopped | null | null | Phase II+ | 489,626,273,281 | Study ended after diabetes development plan review. . | Phase 2 | 31/05/2008 | Terminated | 30/10/2012 | 30/06/2009 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00698789 | Terminated | 2 | 2008-05-01 | Terminated | stopped | null | null | Phase II+ | 489,626,273,281 | Study ended after diabetes development plan review. . | Phase 2 | 31/05/2008 | Terminated | 30/10/2012 | 30/06/2009 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00360698 | Completed | 4 | 2006-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 506,806,141,831 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00360698 | Completed | 4 | 2006-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 506,806,141,831 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00360698 | Completed | 4 | 2006-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 506,806,141,831 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01471808 | Enrolling by invitation | 4 | 2011-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,880,714 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01471808 | Enrolling by invitation | 4 | 2011-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,880,714 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01471808 | Enrolling by invitation | 4 | 2011-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,880,714 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01524705 | Completed | 4 | 2012-08-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,881,084 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01524705 | Completed | 4 | 2012-08-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,881,084 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01524705 | Completed | 4 | 2012-08-01 | null | null | Phase IV | Phase III+ | Phase II+ | 541,165,881,084 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01490658 | Completed | 1 | 2006-06-01 | null | null | null | null | null | 541,165,881,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01490658 | Completed | 1 | 2006-06-01 | null | null | null | null | null | 541,165,881,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01490658 | Completed | 1 | 2006-06-01 | null | null | null | null | null | 541,165,881,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03310749 | Completed | 1 | 2016-01-15 | null | null | null | null | null | 549,755,814,583 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03310749 | Completed | 1 | 2016-01-15 | null | null | null | null | null | 549,755,814,583 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03310749 | Completed | 1 | 2016-01-15 | null | null | null | null | null | 549,755,814,583 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02911792 | Recruiting | 4 | 2016-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 549,755,815,860 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02911792 | Recruiting | 4 | 2016-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 549,755,815,860 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02911792 | Recruiting | 4 | 2016-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 549,755,815,860 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00975286 | Completed | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 584,115,552,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00975286 | Completed | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 584,115,552,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00975286 | Completed | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 584,115,552,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089179 | Completed | 1 | null | null | null | null | null | null | 584,115,553,148 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089179 | Completed | 1 | null | null | null | null | null | null | 584,115,553,148 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089179 | Completed | 1 | null | null | null | null | null | null | 584,115,553,148 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00942318 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 584,115,553,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00942318 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 584,115,553,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00942318 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 584,115,553,746 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00708578 | Completed | 4 | 2008-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,487,979 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00708578 | Completed | 4 | 2008-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,487,979 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00708578 | Completed | 4 | 2008-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,487,979 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089192 | Completed | 1 | null | null | null | null | null | null | 592,705,488,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089192 | Completed | 1 | null | null | null | null | null | null | 592,705,488,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01089192 | Completed | 1 | null | null | null | null | null | null | 592,705,488,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02954692 | Completed | 4 | 2016-11-30 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,488,353 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02954692 | Completed | 4 | 2016-11-30 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,488,353 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02954692 | Completed | 4 | 2016-11-30 | null | null | Phase IV | Phase III+ | Phase II+ | 592,705,488,353 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01702298 | Completed | 3 | 2012-12-07 | null | null | null | Phase III+ | Phase II+ | 609,885,357,727 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
Subsets and Splits